$FUL

Weaver Nathan D. sold $593K of FUL

Weaver Nathan D. (Exec VP, Business Transform.) sold 9,561 shares of FULLER H B CO (FUL) at $62.06 ($0.59M total) on 2026-08-11.

Original reporting
SEC EDGAR · Weaver Nathan D.
Published Aug 12, 2026, 4:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 4:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FUL
Neutral
medium confidence
Mentioned
$FUL
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FULNeutralLow
01

Why it matters

This is a disclosed insider open-market sale (9,561 shares) with no accompanying company news such as earnings, guidance, contracts, or regulatory actions in the text.

02

Market read

Traders may monitor insider activity, but this specific disclosure does not provide new fundamental information to reprice the stock on its own.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the article provides no context for motivation or future trading plans.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-12, sale dated 2026-08-11

Background

The article reports an SEC Form 4 insider transaction for Fuller H B Co (FUL), executed by Exec VP Nathan Weaver.

Company-level read

Ticker impact

$FULNeutralMedium confidence
Context

Form 4 shows Exec VP Nathan Weaver sold 9,561 shares of FUL at $62.0575 on 2026-08-11, totaling $593,331.76.

Expected impact

Likely limited near-term impact; treat as routine insider activity unless paired with other company-specific news.

Evidence & confidence

The article is a primary SEC Form 4 disclosure of an insider sale, with no 10b5-1 plan and no accompanying operational or financial catalyst described.

Market effects

No sector-level implications are provided beyond a single insider transaction.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, but the filing alone does not establish bearish intent or timing advantage.

Key entities

  • FULLER H B CO

    Subject of the Form 4 insider sale disclosure.

  • Weaver Nathan D.

    Exec VP, Business Transform, reported the sale of FUL shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FULMedAI 8/10

H.B. Fuller board rejects unsolicited bid

H.B. Fuller's board rejected an unsolicited bid for its BAS segment, citing a valuation below market precedent and lack of financing details. The board highlighted BAS's 6% organic growth and 10% EBITDA improvement, noting its importance for future earnings. The board also cited operational integration challenges and reaffirmed its strategic priorities, including the Advanced Medical Solutions acquisition and Project Quantum Leap.

$FULMedAI 8/10

H.B. Fuller stock flat as board rejects Ancora’s adhesives bid

H.B. Fuller Co. (NYSE:FUL) shares were unchanged in premarket trading after its board rejected Ancora Holdings Group's $1.2 billion bid for its building adhesives unit, citing undervaluation and lack of growth potential consideration. Ancora criticized the rejection as irrational and emphasized its ability to finance a higher offer. The bid aimed to help H.B. Fuller reduce debt and focus on integrating Advanced Medical Solutions Group Plc.

$FULMed

AMS shareholders approve H.B. Fuller acquisition proposal

H.B. Fuller (NYSE:FUL) said Advanced Medical Solutions Group plc (LSE:AMS) shareholders approved the proposed cash acquisition of AMS. The approval is a milestone toward closing, which H.B. Fuller expects by year end, subject to remaining conditions and regulatory approvals. H.B. Fuller reported 2025 revenue of $3.5B.

$FULMed

Ancora offers up to $1.2bn for an H.B. Fuller business

Activist investor Ancora Holdings proposes an all-cash offer of up to $1.2bn to buy H.B. Fuller’s Building Adhesive Solutions unit, urging divestiture and offering to start due diligence. Ancora, holding over 2% of shares, says it has received no substantive response and may seek board control via a proxy fight. H.B. Fuller shares were down 2.3% intraday.

$FULMed

Why is H B Fuller stock sliding today?

H.B. Fuller shares fell about 1.3% after activist Ancora Holdings disclosed a formal cash offer to buy the company’s Building Adhesive Solutions segment for $1.1 billion to $1.2 billion, escalating a dispute over strategy. Separately, AMS shareholders approved H.B. Fuller’s recommended cash acquisition of Advanced Medical Solutions Group with 84.23% voting in favor. Macro CPI was in line.